Please use this identifier to cite or link to this item: http://dx.doi.org/10.25673/42273
Full metadata record
DC FieldValueLanguage
dc.contributor.refereeWickenhauser, Claudia-
dc.contributor.refereeThomssen, Christoph-
dc.contributor.refereeKantelhardt, Eva Johanna-
dc.contributor.refereeHorn, Lars-Christian-
dc.contributor.authorUngurs, Olga-
dc.date.accessioned2021-12-14T12:40:30Z-
dc.date.available2021-12-14T12:40:30Z-
dc.date.issued2021-
dc.identifier.urihttps://opendata.uni-halle.de//handle/1981185920/44227-
dc.identifier.urihttp://dx.doi.org/10.25673/42273-
dc.description.abstractZielsetzung: Diese Studie hat die Proteinexpression von Insulin-like growth factor 2 mRNA-binding protein 1 in Ovarialkarzinomen untersucht und die Expression zu den klinisch-pathologischen Daten und der Überlebenszeit der Patientinnen korreliert. Material und Methoden: Die Expression von IGF2BP1 wurde an FFPE-Tumorgewebe von 71 Patientinnen mit Ovarialkarzinom untersucht. IHC-Analysen wurden an Primärtumoren und Metastasen mit anti-IGF2BP1-Antikörper durchgeführt. Ergebnisse: 45% (n=32) der Fälle waren IGF2BP1-positiv: 38% (n=19) der Primärtumoren, 36% (n=23) der Peritoneal-, 26% (n=10) der Lymphknoten- und 29% (n=4) der Fernmetastasen. Die Expression korrelierte zu aggressiven Tumoreigenschaften und schlechter Prognose [OS 19 (95% CI 3-36) vs. 53 (28-78) Monate; PFS 14 (11-18) vs. 23 (18-29) Monate, HR 2.028 (0.831-2.691)]. Zusammenfassung: Die Proteinexpression von IGF2BP1 in Ovarialkarzinomen korreliert zu vermindertem Überleben und wird eher in aggressiven Tumoren exprimiert.ger
dc.description.abstractObjective: Insulin-like growth factor 2 mRNA-binding protein 1 has been reported to have prognostic value for cancers. This study aimed to analyse the IGF2BP1 protein expression in ovarian cancer and its correlation to the patients’ data and survival time. Material and methods: IGF2BP1 expression was analysed using FFPE tumour material of 71 patients with ovarian cancer. IHC analyses were performed on primary tumour and metastases with an anti-IGF2BP1 antibody. Results: 45% (n=32) of the cases showed a positive reaction: 38% (n=19) of primary tumours, 36% (n=23) of peritoneal-, 26% (n=10) of lymph node- and 29% (n=4) of distant metastases. The expression of IGF2BP1 correlated to aggressive tumour properties and poor prognosis [OS 19 (95% CI 3-36) resp. 53 (28-78) months; PFS 14 (11-18) resp. 23 (18-29) months, HR 2.028 (0.831-2.691)]. Conclusion: Protein expression of IGF2BP1 correlates to decreased OS and PFS in ovarian cancer and is notably expressed in more aggressive tumours.eng
dc.format.extent1 Online-Ressource (52 Seiten)-
dc.language.isoeng-
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/-
dc.subject.ddc610-
dc.titleThe expression of Insulin-like growth factor 2 mRNA-binding protein 1 in ovarian cancereng
dcterms.dateAccepted2021-09-23-
dcterms.typeHochschulschrift-
dc.typePhDThesis-
dc.identifier.urnurn:nbn:de:gbv:3:4-1981185920-442271-
local.versionTypepublishedVersion-
local.publisher.universityOrInstitutionMartin-Luther-Universität Halle-Wittenberg-
local.subject.keywordsIGF2BP1, IMP1, Ovarialkarzinom, Immunhistochemie, IHC-
local.subject.keywordsIGF2BP1, IMP1, ovarian cancer, immunohistochemistry, IHC-
local.openaccesstrue-
dc.identifier.ppn1782112723-
local.publication.countryXA-DE-
cbs.sru.importDate2021-12-14T12:39:43Z-
local.accessrights.dnbfree-
Appears in Collections:Interne-Einreichungen

Files in This Item:
File Description SizeFormat 
Dissertation_OvCa_IMP1_OU_FINAL_2021.pdf2.11 MBAdobe PDFThumbnail
View/Open